Anti-SARS-CoV-2 Efficacy of Elaeocarpus sylvestris Extract Verified by in silico, in vitro, Preclinical, and Clinical Studies

2022 ◽  
Author(s):  
Hyelin Jeon ◽  
Yeong-Geun Lee ◽  
Yoon Jung Yang ◽  
Yong Joon Jeong ◽  
Ji Hyun Kwon ◽  
...  
Keyword(s):  
Clinical Studies ◽  
In Silico ◽  
Preclinical And Clinical Studies

scholarly journals Essential Oils as Treatment Strategy for Alzheimerʼs Disease: Current and Future Perspectives

Planta Medica ◽  
2018 ◽  
Vol 85 (03) ◽  
pp. 239-248 ◽  
Author(s):  
Anju Benny ◽  
Jaya Thomas
Keyword(s):  
Essential Oils ◽  
Clinical Studies ◽  
Symptomatic Relief ◽  
Memory Loss ◽  
Clinical Trial Data ◽  
In Vivo Studies ◽  
Scientific Databases ◽  
Preclinical And Clinical Studies

AbstractAlzheimerʼs disease is a multifarious neurodegenerative disease that causes cognitive impairment and gradual memory loss. Several hypotheses have been put forward to postulate its pathophysiology. Currently, few drugs are available for the management of Alzheimerʼs disease and the treatment provides only symptomatic relief. Our aim is to review the relevant in vitro, in vivo, and clinical studies focused toward the potential uses of essential oils in the treatment of Alzheimerʼs disease. Scientific databases such as PubMed, ScienceDirect, Scopus, and Google Scholar from April 1998 to June 2018 were explored to collect data. We have conducted wide search on various essential oils used in different models of Alzheimerʼs disease. Out of 55 essential oils identified for Alzheimerʼs intervention, 28 have been included in the present review. A short description of in vivo studies of 13 essential oils together with clinical trial data of Salvia officinalis, Salvia lavandulifolia, Melissa officinalis, Lavandula angustifolia, and Rosmarinus officinalis have been highlighted. In vitro studies of remaining essential oils that possess antioxidant and anticholinesterase potential are also mentioned. Our literary survey revealed encouraging results regarding the various essential oils being studied in preclinical and clinical studies of Alzheimerʼs disease with significant effects in modulating the pathology through anti-amyloid, antioxidants, anticholinesterase, and memory-enhancement activity.

Preparation and, in vitro, preclinical and clinical studies of aceclofenac spherical agglomerates

2008 ◽  
Vol 70 (2) ◽  
pp. 674-683 ◽  
Author(s):  
Achutha Nayak Usha ◽  
Srinivas Mutalik ◽  
Meka Sreenivasa Reddy ◽  
Averineni Kumar Ranjith ◽  
Pralhad Kushtagi ◽  
...  
Keyword(s):  
Clinical Studies ◽  
Spherical Agglomerates ◽  
Preclinical And Clinical Studies

scholarly journals Central role for MCP-1/CCL2 in injury-induced inflammation revealed by in vitro, in silico, and clinical studies

2013 ◽  
Vol 28 (6) ◽  
pp. e28
Author(s):  
Ruben Zamora ◽  
Cordelia Ziraldo ◽  
Rami Namas ◽  
Khalid Almahmoud ◽  
Victor Tapias ◽  
...  
Keyword(s):  
Clinical Studies ◽  
In Silico

scholarly journals Genome Editing Technologies: From Bench Side to Bedside

Acta Medica ◽  
2018 ◽  
Vol 49 (3) ◽  
pp. 30
Author(s):  
Fulya Yaylacıoğlu Tuncay ◽  
Pervin Rukiye Dinçer
Keyword(s):  
Gene Therapy ◽  
Animal Models ◽  
Genome Editing ◽  
Clinical Studies ◽  
Human Gene ◽  
Human Gene Therapy ◽  
Novel Technologies ◽  
Preclinical And Clinical Studies

The development of genome editing technologies has given the chance to researchers to manipulate any genomic sequences precisely. This ability is very useful for creating animal models to study human diseases in vivo; for easy creation of isogenic cell lines to study in vitro and most importantly for overcoming many disadvantages that the researchers faced during the human gene therapy trials. Here we review the basic mechanisms of genome editing technology and the four genome-editing platforms. We also discuss the applications of these novel technologies in preclinical and clinical studies in four groups according to the mechanism used, and lastly, summarize the problems in these technologies.

scholarly journals Does In Vitro Cytochrome P450 Downregulation Translate to In Vivo Drug‐Drug Interactions? Preclinical and Clinical Studies With 13‐ cis ‐Retinoic Acid

2019 ◽  
Vol 12 (4) ◽  
pp. 350-360 ◽  
Author(s):  
Faith Stevison ◽  
Mika Kosaka ◽  
Jane R. Kenny ◽  
Susan Wong ◽  
Cathryn Hogarth ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Retinoic Acid ◽  
Drug Interactions ◽  
Clinical Studies ◽  
Preclinical And Clinical Studies

scholarly journals Ginsenoside Compound K: Insights into Recent Studies on Pharmacokinetics and Health-Promoting Activities

Biomolecules ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. 1028 ◽  
Author(s):  
Anshul Sharma ◽  
Hae-Jeung Lee
Keyword(s):  
Clinical Studies ◽  
Water Solubility ◽  
Parent Compound ◽  
Clinical Trial Data ◽  
In Vivo Studies ◽  
Compound K ◽  
Health Promoting ◽  
Preclinical And Clinical Studies

Ginseng (Panax ginseng) is an herb popular for its medicinal and health properties. Compound K (CK) is a secondary ginsenoside biotransformed from major ginsenosides. Compound K is more bioavailable and soluble than its parent ginsenosides and hence of immense importance. The review summarizes health-promoting in vitro and in vivo studies of CK between 2015 and 2020, including hepatoprotective, anti-inflammatory, anti-atherosclerosis, anti-diabetic, anti-cancer, neuroprotective, anti-aging/skin protective, and others. Clinical trial data are minimal and are primarily based on CK-rich fermented ginseng. Besides, numerous preclinical and clinical studies indicating the pharmacokinetic behavior of CK, its parent compound (Rb1), and processed ginseng extracts are also summarized. With the limited evidence available from animal and clinical studies, it can be stated that CK is safe and well-tolerated. However, lower water solubility, membrane permeability, and efflux significantly diminish the efficacy of CK and restrict its clinical application. We found that the use of nanocarriers and cyclodextrin for CK delivery could overcome these limitations as well as improve the health benefits associated with them. However, these derivatives have not been clinically evaluated, thus requiring a safety assessment for human therapy application. Future studies should be aimed at investigating clinical evidence of CK.

Immuno-nanocarriers for brain delivery: limitations from in vitro to preclinical and clinical studies

Nanomedicine ◽  
2020 ◽  
Vol 15 (6) ◽  
pp. 543-545 ◽  
Author(s):  
Joana A Loureiro ◽  
Maria João Ramalho ◽  
Maria do Carmo Pereira
Keyword(s):  
Clinical Studies ◽  
Brain Delivery ◽  
Preclinical And Clinical Studies

scholarly journals Stromal Vascular Fraction and Amniotic Epithelial Cells: Preclinical and Clinical Relevance in Musculoskeletal Regenerative Medicine

2021 ◽  
Vol 2021 ◽  
pp. 1-22
Author(s):  
Francesca Veronesi ◽  
Melania Maglio ◽  
Deyanira Contartese ◽  
Lucia Martini ◽  
Aurelio Muttini ◽  
...  
Keyword(s):  
Regenerative Medicine ◽  
Clinical Studies ◽  
Musculoskeletal Diseases ◽  
Stromal Vascular Fraction ◽  
Cell Types ◽  
Long Term Results ◽  
Musculoskeletal Tissue ◽  
Preclinical And Clinical Studies ◽  
Different Cell Types

Musculoskeletal regenerative medicine is mainly based on the use of cell therapy to heal damaged tissues such as bone, cartilage, and tendons. Throughout the years, different cell types have been employed for the treatment of musculoskeletal diseases, in particular, mesenchymal stem cells (MSCs) derived from bone marrow (BMSCs) and adipose tissue (ADSCs). Though the results of these literature studies have been encouraging, there are some limitations, especially on long-term results. Recently, some interest has shifted towards new cell types such as the stromal vascular fraction (SVF) and amniotic endothelial cells (AECs). The aim of the present literature review is to evaluate preclinical and clinical studies that used SVF and AECs for musculoskeletal tissue regeneration. Forty-eight preclinical and clinical studies, performed in the last 10 years, were identified. Both SVF and AECs, injected or implanted with or without scaffolds, were shown to be valid alternatives, and in some ways superior, to ADSCs and BMSCs, being able to differentiate towards osteogenic, chondrogenic, and tenogenic lineages, and to promote cell and tissue regenerative potential. The use of SVF and AECs could represent a new regenerative treatment in several musculoskeletal pathologies, solving the problem of cell expansion in vitro.

scholarly journals Platelet-Rich Plasma for Bone Fracture Treatment: A Systematic Review of Current Evidence in Preclinical and Clinical Studies

2021 ◽  
Vol 8 ◽  
Author(s):  
Yangming Zhang ◽  
Fei Xing ◽  
Rong Luo ◽  
Xin Duan
Keyword(s):  
Systematic Review ◽  
Bone Fracture ◽  
Clinical Studies ◽  
Platelet Rich Plasma ◽  
Fracture Treatment ◽  
Preclinical Studies ◽  
Preclinical And Clinical Studies ◽  
Positive Effect ◽  
Present Systematic Review

Background: Recently, there is an increasing interest in the therapeutic potential of platelet-rich plasma (PRP) for bone fracture treatment. Nevertheless, the effect of PRP for bone fracture treatment remains controversial and is still a matter of discussion. Therefore, we performed a systematic review to evaluate the efficacy and safety of PRP injection for treatment of bone fracture.Methods: The main bibliographic databases, including Medline, PubMed, Embase, Web of Science, and the Cochrane library, were comprehensively searched for studies focusing on the application of platelet-rich plasma (PRP) on bone fracture treatment. All relevant articles were screened for eligibility and subdivided into the preclinical and clinical studies. Data were extracted and presented systematically.Results: Finally, twenty-six in vitro preclinical studies (basic studies), nine in vivo preclinical studies (animal studies), and nine clinical studies, met the selection criteria, and were included in the present systematic review. Preclinical studies showed an overall positive effect of PRP on osteoblast-like cells in vitro and bone healing in animal models. The most used treatment for bone fracture in animal and clinical studies is fixation surgery combined with PRP injection. The clinical studies reported PRP shortened bony healing duration, and had no positive effect on improving the healing rate of closed fractures. However, the results of functional outcomes are controversial. Additionally, compared with control group, PRP would not increase the rate of postoperative wound infection.Conclusion: The present systematic review confirmed the continuing interests of PRP as an additional treatment for bone fracture. Preclinical studies highlighted the potential value of PRP as promising therapy for bone fracture. However, the preclinical evidence did not translate into a similar result in the clinical studies. In addition, types of fractures and procedures of PRP preparation are heterogeneous in enrolled studies, which might result in controversial results. Meanwhile, characteristics of PRP, such as platelet concentration, the numbers of leukocytes, still need to be determined and further research is required.

Sign in / Sign up

Export Citation Format

Share Document